Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Targeting the epigenome: towards a better understanding of disease pathogenesis and novel therapeutic strategies in Multiple Sclerosis

Project description

Epigenetic therapies for multiple sclerosis

Multiple sclerosis (MS) is a progressive immune-associated disorder of unknown cause. The EU-funded Epi4MS project is working under the hypothesis that MS is triggered by epigenetic changes which affect gene expression but not the genetic code. Researchers will identify and link epigenetic states with MS pathogenesis and test the therapeutic potential of targeted epigenome editing in mouse models of the disease. Results will help determine the underlying molecular mechanisms of MS and pave the way for innovative treatments. Moreover, they will lay the foundation for reversing aberrant epigenetic states in other aggressive immune-related diseases.

Objective

Multiple Sclerosis (MS) is a leading cause of unpredictable and incurable progressive disability in young adults. Although the exact cause remains unknown, this immune-mediated disease is likely triggered by environmental factors in genetically predisposed individuals. I propose that epigenetic mechanisms, which regulate gene expression without affecting the genetic code, mediate the processes that cause MS and that aberrant epigenetic states can be corrected, spearheading the development of alternative therapies. We will exploit the stable and reversible nature of epigenetic marks, in particular DNA methylation, to gain insights into the novel modifiable disease mechanisms by studying the target organ in a way that has not been possible before. This highly ambitious project comprises three synergistic facets formulated in specific aims to: (i) identify epigenetic states that characterize the pathogenesis of MS, (ii) prioritize functional epigenetic states using high-throughput epigenome-screens, and (iii) develop novel approaches for precision medicine based on correcting causal epigenetic states. Our unique MS biobank combined with cutting-edge methodologies to capture pathogenic cells and measure their functional states provides a rational starting point to identify MS targets. I will complement this approach with studies of the functional impact of MS targets using innovative in vitro screens, with the added value of unbiased discovery of robust regulators of specific MS pathways. Finally, my laboratory has extensive experience with animal models of MS and I will utilize these powerful systems to dissect molecular mechanisms of MS targets and test the therapeutic potential of targeted epigenome editing in vivo. Our findings will set the stage for a paradigm-shift in studying and treating chronic inflammatory diseases based on preventing and modulating aggressive immune responses by inducing self-sustained reversal of aberrant epigenetic states.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

ERC-COG - Consolidator Grant

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2018-COG

See all projects funded under this call

Host institution

KAROLINSKA INSTITUTET
Net EU contribution
€ 1 998 798,00
Address
NOBELS VAG 5
171 77 STOCKHOLM
Sweden
Region
Östra Sverige Stockholm Stockholms län
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 998 798,00

Beneficiaries (1)